Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
Bowel cancer’s 'big bang' moment revealed
Like the astronomical explosion that kickstarted the universe, bowel cancer has a 'Big Bang' moment which determines how it will grow, according to new research from scientists at The Institute of Cancer Research, London.
ICR rated one of UK’s leading academic centres for industry collaboration and commercialisation
The Institute of Cancer Research has ranked among the top UK universities for research partnerships and commercialisation.
Legendary jockey Bob Champion awarded honorary doctorate at ICR graduation ceremony
Legendary jockey Bob Champion has been awarded an honorary doctorate by The Institute of Cancer Research, London, in recognition of his outstanding contribution in supporting research into male cancers at a ceremony at London’s Guildhall.
Scientists discover new weakness in drug-resistant sarcomas, offering hope for smarter treatment strategies
In a major step forward for cancer research, scientists have uncovered a surprising vulnerability in soft tissue sarcomas – a rare and aggressive group of cancers that affect the soft tissues of the body, such as muscle, fat and blood vessels.